Publication | Closed Access

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

Molecular PharmacologyMedicinal ChemistryDrug TargetBiochemistryP53–mdm2 InteractionDrug DiscoveryMedicineNatural SciencesRational Drug DesignMolecular BiologyConformational StudyNovel ClassMolecular DockingMolecular ModelingConformational ArgumentStructural BiologyMolecular Design